Abediterol

Abediterol

225px
Systematic (IUPAC) name
5-[(1R)-2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}- 1-hydroxyethyl]-8-hydroxyquinolin-2(1H)-one
Clinical data
Legal status	Experimental
Routes of administration	Inhalation
Pharmacokinetic data
Biological half-life	24.3 hours
Identifiers
CAS Number	915133-65-2
ATC code	None
PubChem	CID: 11962616
ChemSpider	10136846 Y
UNII	QXA167CM6F Y
KEGG	DG01232 Y
ChEMBL	CHEMBL3039530 Y
Chemical data
Formula	C25H30F2N2O4
Molecular mass	403.898 g/mol
SMILES FC(F)(c1ccccc1)COCCCCCCNC[C@H](O)c3ccc(O)c2c3\C=C/C(=O)N2
InChI InChI=1S/C25H30F2N2O4/c26-25(27,18-8-4-3-5-9-18)17-33-15-7-2-1-6-14-28-16-22(31)19-10-12-21(30)24-20(19)11-13-23(32)29-24/h3-5,8-13,22,28,30-31H,1-2,6-7,14-17H2,(H,29,32)/t22-/m0/s1 Y Key:SFYAXIFVXBKRPK-QFIPXVFZSA-N Y

Abediterol (INN) (codenamed AZD-0548, LAS 100977) is a novel, once-daily experimental drug candidate for the treatment of asthma and chronic obstructive pulmonary disease (COPD). It is currently under development by the Spanish pharmaceutical company Almirall and is in Phase II clinical trials.

It acts as a β₂ adrenergic agonist and is classified as an ultra-long-acting β₂ agonist (ultra-LABA).

Its coformulation with mometasone furoate is also in Phase II clinical trials.